New Delhi, March 31 Novo Nordisk India announced on Tuesday reductions in the prices of Ozempic and Wegovy in India, days after the launch of generic versions of semaglutide injections for patients with type 2 diabetes and obesity.
Indian pharmaceutical companies recently announced the launch of their generic versions, following the expiration of patents on the active ingredient in products like Ozempic and Wegovy.
Effective April 1, 2026, the price of the initial dose of Ozempic will be reduced by 36%, while the price of the initial dose of Wegovy will be reduced by 48% in India.
Ozempic (0.25 mg) and Wegovy (0.25 mg) will be available in India at an effective daily price of ₹202 or a weekly price of ₹1,415, inclusive of taxes, Novo Nordisk stated.
The prices of the generic versions of semaglutide injection are considerably lower than those of the original products, Novo Nordisk.
The company said that it has lowered prices "to make these innovative therapies, which are supported by robust clinical evidence and high scientific standards, more accessible to a larger section of people living with diabetes and obesity in India".
Novo Nordisk India Managing Director Vikrant Shrotriya said, "By revising the price of our innovative treatments, we are trying to make the best available cardiometabolic care more affordable for as many people with type 2 diabetes, overweight, and obesity in India as possible. The burden of diabetes, obesity, and related complications is immense for India, and we aim to address this challenge with effective, safe, and proven solutions."